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OBJECTIVES The aim of the study was to evaluate the relationship between symptom-onset-to-balloon
time and one-year mortality in patients with ST-segment elevation myocardial infarction
(STEMI) treated by primary angioplasty.
BACKGROUND Despite the prognostic implications demonstrated in patients with STEMI treated with
thrombolysis, the impact of time-delay on prognosis in patients undergoing primary
angioplasty has yet to be established.
METHODS Our study population consisted of 1,791 patients with STEMI treated by primary angioplasty
from 1994 to 2001. All clinical, angiographic and follow-up data were collected. Subanalyses
were conducted according to patient risk profile at presentation and preprocedural Throm-
bolysis In Myocardial Infarction (TIMI) flow.
RESULTS A total of 103 patients (5.8%) had died at one year. Symptom-onset-to-balloon time was
significantly associated with the rate of postprocedural TIMI 3 flow (p  0.012), myocardial
blush grade (p  0.033), and one-year mortality (p  0.02). A stronger linear association
between symptom-onset-to-balloon time and one-year mortality was observed in non-low-
risk patients (p  0.006) and those with preprocedural TIMI flow 0 to 1 (p  0.013). No
relationship was found between door-to-balloon time and mortality. At multivariate analysis,
a symptom-onset-to-balloon time 4 h was identified as an independent predictor of
one-year mortality (p  0.05).
CONCLUSIONS This study shows that, in patients with STEMI treated by primary angioplasty, symptom-
onset-to-balloon time, but not door-to-balloon time, is related to mortality, particularly in
non–low-risk patients and in the absence of preprocedural anterograde flow. Furthermore, a
symptom-onset-to-balloon time 4 h was identified as independent predictor of one-year
mortality. (J Am Coll Cardiol 2003;42:991–7) © 2003 by the American College of
Cardiology Foundation
The improvement in the management of patients with
ST-segment elevation myocardial infarction (STEMI)
characterized by early diagnosis and treatment of the acute
event, improved management of complications, and general
availability of pharmacologic and mechanical therapies has
significantly reduced cardiac mortality (1–5).
Although a clear relationship between mortality and time
delay from symptom-onset to treatment has been demon-
strated in patients with STEMI treated by thrombolysis
(6–8), the impact of time delay on prognosis in patients
undergoing primary angioplasty still has not been clarified
(8–11). The aim of the current study was to evaluate the
influence of symptom-onset-to-balloon time and door-to-
balloon time on mortality in a large cohort of patients with
STEMI treated by primary angioplasty.
METHODS
From 1994 to 2001, a total of 1,791 patients with STEMI
fulfilled the criteria for entry into one of the trials (Table 1)
at our institution (4,12–15). Informed consent was obtained
from each patient (or from their relatives in case of patient’s
inability) before the angiogram. Our study was approved by
the institutional review board. All patients presenting
within 6 h from symptom onset, or between 6 and 24 h if
they had continuous symptoms and signs of ischemia
(persistent or recurrent chest pain and/or persistent eleva-
tion or re-elevation of ST-segment) were included (4). All
patients received aspirin (500 mg intravenously) and heparin
(10,000 IU intravenously) before the procedure. Because the
benefits of IIb/IIIa inhibitors has only been proved recently
(16), most of our trials have been conducted without
IIb/IIIa inhibitors, with 5% of patients in the current
study treated with this additional therapy. All patients were
on aspirin after the procedure. Therapy after stenting has
changed across the study period. Patients have been treated
with additional three-month warfarin therapy before 1996,
and additional one-month antiplatelet therapy with ticlopi-
dine after 1996.
According to the time from symptom onset to first
balloon inflation (symptom-onset-to-balloon time), patients
were divided into four groups (2 h, between 2 and 4 h,
between 4 and 6 h, and 6 h). According to the time from
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hospitalization to first balloon inflation (door-to-balloon
time), patients were divided into four groups (30 min,
between 31 and 60 min, between 61 to 90 min, and 90
min).
The presence of one or more Thrombolysis In Myocar-
dial infarction (TIMI) criteria (previous myocardial infarc-
tion, anterior infarction, systolic blood pressure 100 mm
Hg, sinus tachycardia, atrial flutter or fibrillation, age 70
years, rales extending upward to cover more than one-third
of the lung fields, pulmonary edema, or cardiogenic shock)
was used to stratify patients into “low-risk” and “non–low-
risk” patients (17).
Angiographic data analysis. All angiograms have been
reviewed by two experienced investigators who were blinded
to all data apart from the coronary angiogram; TIMI flow
grades and myocardial blush grade (MBG) were assessed
after the angioplasty procedure, as previously described (18).
Residual stenosis was visually assessed. Procedural success
was defined as postprocedural TIMI 3 flow and a residual
stenosis 50%.
Enzymatic infarct size. Enzymatic infarct size was calcu-
lated, as previously described, by cumulative enzyme release
(LDHQ48) from serial measurements up to 48 h after
symptom onset (19).
Clinical outcome. Records of included patients who vis-
ited our outpatient clinic were reviewed. For all other
patients, information was obtained from the patient’s gen-
eral physician or by direct telephone interview with the
patient. For patients who died during follow-up, hospital
records and necropsy data were reviewed. No patient was
lost to follow-up.
Statistical analysis. Statistical analysis was performed with
the SPSS 10.0 statistical package. Continuous data were
expressed as mean SD and categorical data as percentage.
Analysis of variance was used for continuous variables.
The chi-square test or the Fisher exact test (in case the
expected value of the variable was 5 in at least one group)
was used for categorical variables. A p value 0.05 was
considered statistically significant.
The difference in event rates between groups during the
follow-up period was assessed by the Kaplan-Meier method
using the log-rank test. Multivariate analysis was performed
by use of the Cox proportional hazard method. The step-
wise selection of variables and estimation of significant
probabilities were computed by means of maximal likeli-
hood ratio test. The chi-square value was calculated from
the log of the ratio of maximal partial likelihood functions.
The additional value of each category of variables added
sequentially was evaluated on the basis of the increases in
the overall likelihood statistic ratio.
RESULTS
Symptom-onset-to-balloon time and door-to-balloon time
were, respectively, 214  189 min and 55  36 min.
Demographic, clinical, and angiographic characteristics ac-
cording to symptom-onset-to-balloon time and door-to-
balloon time are reported in Tables 2 and 3, respectively. All
categorical variables were analyzed using the chi-square test,
except for previous angioplasty and previous bypass surgery
(Fisher exact test). An association was found between these
two parameters, with age and gender. A higher incidence of
anterior infarction, Killip class 1, and larger enzymatic
infarct size were observed in patients with short door-to-
balloon time. Symptom-onset-to-balloon time, but not
door-to-balloon time, was significantly associated with the
rate of postprocedural TIMI 3 flow, procedural success, and
MBG 2 to 3.
A total of 103 patients (5.8%) had died at one-year
follow-up. No difference in mortality was observed among
patients treated in the first (1994 to 1997) and last four years
(1998 to 2001) of the study (5.9% vs. 4.2%, respectively; p
 NS). No difference in mortality was observed between
patients who were transferred (n  692) or not transferred
(n  1,099) from other hospitals (6.2% vs. 5.5%, respec-
tively, p  NS). As depicted in Figure 1, cardiac mortality
was related to symptom-onset-to-balloon time (p  0.02),
but not to door-to-balloon time (Fig. 2).
Symptom-onset-to-balloon time, door-to-balloon time,
and mortality in low-risk and non–low-risk patients.
The relation between symptom-onset-to-balloon time,
door-to-balloon time, and mortality was also investigated in
low-risk patients and non–low-risk patients. A total of 545
low-risk patients (30.4%) and 1,246 (69.6%) non–low-risk
patients were identified (with a one-year mortality of 1.1%
vs. 7.8%, respectively; p  0.0001). As depicted in Fig. 1,
Abbreviations and Acronyms
LDHQ48  enzymatic infarct size from serial
measurements of lactate dehydrogenase
MBG  myocardial blush grade
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Characteristics of Randomized Trials Conducted at
Our Institution in Patients With Acute Myocardial Infarction,
and the Number of Patients Included From Each Trial in the
Current Study
1) Randomized comparison between primary angioplasty or
thrombolysis in low-risk patients (45 patients) (12)
2) Randomized comparison between balloon and stenting in primary
angioplasty (227 patients) (4)
3) Randomized comparison of intra-aortic balloon pump in high-risk
patients after primary angioplasty (150 patients) (13)
4) Randomized comparison of high-dose (20,000 IU) vs. low-dose
heparin (5,000 IU) in primary angioplasty (584 patients) (14)
5) Randomized comparison between thrombolysis and primary
angioplasty in elderly ( 75 yrs) (46 patients) (15)
6) Randomized comparison of glucose-insulin-potassium solution
infusion in primary angioplasty (739 patients)*
*Accepted for publication in J Am Coll Cardiol.
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mortality increased linearly according to symptom-onset-
to-balloon time only in patients with non-low-risk charac-
teristics (p  0.006). As shown by Kaplan-Meier survival
curves (Fig. 3), the difference in mortality among the four
groups was already observed at 30 days, and persisted until
one-year follow-up. No relationship was observed between
door-to-balloon time and mortality either in low-risk or
non–low-risk patients (Fig. 2).
Symptom-onset-to-balloon time, door-to-balloon time,
and mortality according to preprocedural TIMI flow. To
investigate the impact of preprocedural TIMI flow on the
prognostic role of symptom-onset-to-balloon time and
door-to-balloon time, patients were classified according to
preprocedural TIMI 0 to 1 flow (1,321 patients [73.8%])
and TIMI 2 to 3 flow (470 patients [26.2%]). A linear
relationship between symptom-onset-to-balloon time and
one-year mortality was observed only in patients with
preprocedural TIMI 0 to 1 flow, but not in patients with
preprocedural TIMI 2 to 3 flow (Fig. 1). The relationship
between door-to-balloon time and mortality was not af-
fected by preprocedural TIMI flow (Fig. 2).
Multivariate predictors of one-year mortality. As shown
in Table 4, a symptom-onset-to-balloon time 4 h (p 
0.05) was an independent predictor of one-year mortality,
together with Killip 1, age 70 years, postprocedural
TIMI 0 to 2 flow, anterior MI, and multivessel disease.
DISCUSSION
The main finding of the present study is that, among
patients with STEMI undergoing mechanical reperfusion,
symptom-onset-to-balloon time, but not door-to-balloon
Table 2. Demographic, Clinical, and Angiographic Characteristics According to Symptom-
Onset-to-Balloon Time
<2 h 2–4 h 4–6 h >6 h p Value
Number of patients 226 1,065 427 73
Age (yrs) 59  11 60  11 61  12 62  13 0.01
Male gender (%) 79.2 81.9 76.3 58.9  0.001
Diabetes (%) 8 7.8 9.4 17.8 NS
Previous MI (%) 11.1 11.5 12.6 4.1 NS
Anterior MI or LBBB (%) 51.8 51.5 48 61.6 NS
Killip class 1 (%) 13.7 11.9 10.5 11.8 NS
Transferred patients (%) 25.7 41 40 35.6  0.0001
Multivessel disease (%) 44.7 55.1 56.4 46.6 NS
Pre-TIMI 0–1 flow (%) 74.8 72.4 76.3 75.3 NS
Post-TIMI 3 flow (%) 93.4 91.3 86.9 90.4 0.012
Procedural success (%) 92.4 89.8 85.9 89.6 0.01
MBG 2–3 (%)* 80 75.8 70.8 76.8 0.033
Stent (%) 55.3 47.9 50.3 52.1 NS
LDHQ48 (U/l)† 1,632  1,712 1,858  1,552 1,834  1,510 1,815  1,557 NS
*Data available in 1,771 patients; †data available in 1,069 patients.
LBBB  left anterior bundle branch; LDHQ48  enzymatic infarct size from serial measurements of lactate dehydrogenase;
MBG  myocardial blush grade; MI  myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
Table 3. Demographic, Clinical, and Angiographic Characteristics According to Door-to-
Balloon Time
<30 min 31–60 min 61–90 min >90 min p Value
Number of patients 409 768 416 198
Age (yrs) 59  11 60  11 61  11 62  13 0.01
Male gender (%) 81.4 79.6 79.6 73.2 0.047
Diabetes (%) 7.1 8.5 7.9 13.7 NS
Previous MI (%) 10.3 10.8 13.2 12.1 NS
Anterior MI or LBBB (%) 68.7 49.5 42.3 41.9  0.001
Killip class  1 (%) 15.4 11.7 8.4 12.1 0.021
Transferred patients (%) 70.4 37.1 22.1 13.6  0.0001
Multivessel disease (%) 50.4 53.8 56.3 55.6 NS
Pre-TIMI 0–1 flow (%) 72.9 74.3 74 72.7 NS
Post-TIMI 3 flow (%) 90.2 91.7 89.9 87.4 NS
Procedural success (%) 89.2 90.2 88.8 86.5 NS
MBG 2–3 (%)* 73.9 76.8 75.8 69.9 NS
Stent (%) 50.6 49.6 49.5 49.5 NS
LDHQ48 (U/l)† 2,082  1,836 1,821  1,576 1,696  1,382 1,606  1,382 0.018
*Data available in 1,771 patients; †data available in 1,069 patients.
Abbreviations as in Table 1.
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time, affects one-year mortality, particularly in high-risk
patients and in the absence of preprocedural TIMI 2 to 3
flow. In this study, a symptom-onset-to-balloon time 4 h
has been shown to be an independent predictor of one-year
mortality.
Symptom-onset-to-balloon time and mortality in
STEMI. The aim of a successful therapeutic strategy in
STEMI is to restore myocardial flow as soon as possible
from symptom onset. Despite the demonstrated prognostic
role of time to therapy in patients with STEMI treated by
thrombolysis (6–8), there is still doubt with regard to its
role in patients treated with primary angioplasty (8–11).
Brodie et al. (9) observed a better outcome among
patients undergoing primary angioplasty within 2 h from
symptom onset, whereas a relatively stable mortality rate
was observed between 2 to 12 h. These data were confirmed
by Cannon et al. (11) who, in a cohort of 27,080 patients
undergoing primary angioplasty, found only door-to-
balloon time, but not symptom-onset-to-balloon time, to be
associated with mortality.
Consistent with these data, Zijlstra et al. (8), in a recent
pooled-analysis of several randomized trials comparing pri-
mary angioplasty and thrombolysis, found a direct relation-
ship between time from symptom onset to treatment only in
patients treated by thrombolysis, but not by primary angio-
plasty.
A major limitation of these studies is that they did not
stratify patients according to the risk of death. In fact, it
seems unlikely to show a prognostic role of time delay in
patients at very low-risk of death.
Another limitation of these studies is that all patients
were included in the analysis, without any information on
preprocedural TIMI flow. Pre-angioplasty TIMI flow may
significantly limit the accuracy of time from symptom-
onset-to-first-balloon inflation as a parameter of total isch-
emia time. In fact, in those patients, total ischemia time is
shorter than that from symptom-onset-to-balloon inflation.
In contrast with previous studies, we analyzed the prog-
nostic role of symptom-onset-to-balloon time according to
patient risk profile. Using TIMI criteria (17), we identified
a non–low-risk population, and we found a significant
relationship between symptom-onset-to-balloon time and
mortality in these patients but not in low-risk patients.
We also analyzed the impact of preprocedural flow on the
prognostic role of time delay, and we found a significant
relationship between symptom-onset-to-balloon time and
Figure 1. Bar graphs show the relationship between symptom-onset-to-balloon time and one-year mortality, in all patients, in low- and non–low-risk
patients (upper graph), and according to preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow (lower graph).
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mortality in patients with preprocedural TIMI flow 0 to 1.
No relationship was found between door-to-balloon time
and mortality, even if the analysis was conducted according
to the patient risk profile and preprocedural TIMI flow.
In our study, a symptom-onset-to-balloon time 4 h
was, together with Killip class (20), postprocedural TIMI
flow (21), age (22,23), multivessel disease (24), and anterior
infarction, (24) an independent predictor of one-year mor-
tality.
Consistent with our data, Antoniucci et al. (25) found, in
a population of 1,332 patients undergoing primary angio-
plasty, a relationship between time-delay and mortality in
high-risk patients.
Several explanations may account for our findings. As
demonstrated in animal models (26–28), the duration of
coronary occlusion is a main determinant of infarct size.
Therefore, late reperfusion is expected to result in less
myocardial salvage and, conceivably, in a higher mortality
rate, in comparison with early reperfusion, even when
optimal mechanical reperfusion is applied. Supporting the
prognostic role of early restoration of antegrade flow in
STEMI, Stone et al. (24) found preprocedural TIMI 3 flow
to be an independent predictor of mortality. Furthermore, a
delay in reperfusion may be associated with an older,
organized intracoronary thrombus, in comparison with an
early reperfusion. This may result in a higher incidence of
distal embolization with a lower postprocedural TIMI 3
flow and a poor myocardial perfusion (18,29). In our study,
a delayed reperfusion (4 h) was associated with a lower
rate of postprocedural TIMI 3 flow and MBG 2 to 3.
Some investigators have found a relation between door-
to-balloon time and outcome in multicenter studies (10,11).
However, in these settings, door-to-balloon time is proba-
bly a surrogate for quality of care. This confounding
mechanism does not play a role in single center studies. The
absence of any relationship between door-to-balloon time
and mortality in our study is also explained by the fact that
this parameter represents only a part of the total ischemia
time. Furthermore, we found a higher incidence of anterior
infarction, Killip class 1, and larger enzymatic infarct size
in patients with a shorter door-to-balloon time (30 min).
This is a consequence of our policy. In fact, quite all
patients, according to a regional project, are transferred to
our hospital from other hospitals of our region, or directly
from home after the in-ambulance diagnosis of a large acute
infarction. Thus, we try, as previously described, to keep the
door-to-balloon time as short as possible, particularly in
high-risk patients (30).
Study limitations. This is an observational study of pa-
tients enrolled in randomized trials at our Institution, thus,
Figure 2. Bar graphs show the relationship between door-to-balloon time and one-year mortality, in all patients, in low- and non–low-risk patients (upper
graph), and according to preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow (lower graph).
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potentially, at lower risk in comparison with patients in the
daily clinical practice. Enzymatic infarct size was not avail-
able in all patients, with a potential underestimation of the
impact of an early treatment on myocardial salvage.
Despite the limited use of stenting (in 50% of patients)
and abciximab (in 5%) in the present study, currently
available data do not show a reduction of mortality by
additional use of stenting and abciximab, even with their
combination (5).
The lack of an effect of door-to-balloon time may be
explained by the shorter door-to-balloon time, when com-
pared with previous reports (11).
Clinical implications. Although primary angioplasty has
been demonstrated to be superior to thrombolytic therapy
(2,3), several areas for improvement still remain. Transpor-
tation to a tertiary center with angioplasty facilities has been
shown to be safe and feasible (31–33). However, the
potential time delay for transportation remains a major
drawback to primary angioplasty.
The results of our study suggest that, in patients with
STEMI undergoing primary angioplasty, all efforts should
be made to shorten the time between symptom onset and
mechanical reperfusion, particularly in high-risk patients.
Conclusions. This study shows that, in patients with
STEMI treated by primary angioplasty, symptom-onset-to-
balloon time, but not door-to-balloon time, is related to
mortality, particularly in high-risk patients and in the
Figure 3. Kaplan-Meier survival curves according to symptom-onset-to-balloon time in both low-risk (upper graph) and non–low-risk patients (lower
graph).
Table 4. Predictors of One-Year Mortality at Multivariate
Analysis
Odds Ratio
(95% CI) p Value
Killip class (1) 5.27 (3.4–8.1)  0.0001
Age (70 yrs) 2.98 (1.9–4.5)  0.0001
TIMI flow 0–2 post 2.96 (1.84–4.71)  0.0001
Anterior infarction 2.13 (1.34–3.37) 0.001
Multivessel disease 2.34 (1.42–3.8) 0.001
Symptom-onset-to-balloon (4 h) 1.55 (1.01–2.4) 0.046
Procedural success 1.57 (0.72–3.42) NS
Preprocedural TIMI 0–1 flow 1.32 (0.77–2.26) NS
Previous infarction 0.9 (0.51–1.58) NS
Diabetes 0.97 (0.52–1.8) NS
CI  confidence interval; TIMI  Thrombolysis In Myocardial Infarction.
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absence of preprocedural anterograde flow. Furthermore, a
symptom-onset-to-balloon time 4 h was identified as an
independent predictor of one-year mortality.
Reprint requests and correspondence: Dr. Harry Suryapranata,
ISALA Klinieken, Hospital De Weezenlanden, Department of
Cardiology, Groot Wezeland 20, 8011 JW Zwolle, the Nether-
lands. E-mail: h.suryapranata@diagram-zwolle.nl.
REFERENCES
1. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA
guidelines for the management of patients with acute myocardial
infarction: executive summary and recommendations: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). Circulation 1999;100:1016–30.
2. Grines CL, Browne KF, Marco J, et al. A comparison of immediate
angioplasty with thrombolytic therapy for acute myocardial infarction:
the Primary Angioplasty in Myocardial Infarction study group. N Engl
J Med 1993;328:673–9.
3. Zijlstra F, Hoorntje JCA, de Boer MJ, et al. Long-term benefit of
primary angioplasty as compared with thrombolytic therapy for acute
myocardial infarction. N Engl J Med 1999;341:1413–9.
4. Suryapranata H, van’t Hof A, Hoorntje JCA, de Boer MJ, Zijlstra F.
Randomized comparison of coronary stenting with balloon angioplasty
in selected patients with acute myocardial infarction. Circulation
1998;97:2502–5.
5. Stone G, Grines CL, Cox AD, et al., for the Controlled Abciximab
and Device Investigation to Lower Late Angioplasty Complications
(CADILLAC) Investigators. Comparison of angioplasty with stenting
with or without abciximab, in acute myocardial infarction. N Engl
J Med 2002;346:957–66.
6. Fibrinolityc Therapy Trialists’ (FTT) Collaborative Group. Indica-
tions for fibrinolytic therapy and suspected acute myocardial infarction:
collaborative overview of early mortality and major morbidity results
from all randomised trials of more than 1000 patients. Lancet
1994;343:311–22.
7. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset
to treatment and outcomes after thrombolyitc therapy. J Am Coll
Cardiol 1996;27:1646–55.
8. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome
of patients with early (2 h), intermediate (2–4 h) and late (4 h)
presentation treated by primary coronary angioplasty or thrombolytic
therapy for acute myocardial infarction. Eur Heart J 2002;23:550–7.
9. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to
reperfusion for 30-day and late survival and recovery of left ventricular
function after primary angioplasty for acute myocardial infarction.
J Am Coll Cardiol 1998;32:1312–9.
10. Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay in
performing direct coronary angioplasty and early clinical outcome in
patients with acute myocardial infarction: results from the Global Use
of Strategies to Open Occluded Arteries in Acute Coronary Syn-
dromes (GUSTO IIb) trial. Circulation 1999;100:14–20.
11. Cannon GP, Gibson GM, Lambrew CT, et al. Relationship of
symptom-onset-to-balloon time and door-to-balloon time with mor-
tality in patients undergoing angioplasty for acute myocardial infarc-
tion. JAMA 2000;283:2941–7.
12. Zijlstra F, Beukema WP, van’t Hof AW, et al. Randomized compar-
ison of primary coronary angioplasty with thrombolytic therapy in low
risk patients with acute myocardial infarction. J Am Coll Cardiol
1997;29:908–12.
13. van’t Hof AW, Liem AL, de Boer MJ, Hoorntje JC, Suryapranata H,
Zijlstra F. A randomized comparison of intra-aortic balloon pumping
after primary coronary angioplasty in high risk patients with acute
myocardial infarction. Eur Heart J 1999;20:659–65.
14. Liem A, Zijlstra F, Ottervanger JP, et al. High dose heparin as
pretreatment for primary angioplasty in acute myocardial infarction:
the Heparin in Early Patency (HEAP) randomized trial. J Am Coll
Cardiol 2000;35:600–4.
15. de Boer MJ, Ottervanger JP, van’t Hof AW, Hoorntje JC, Surya-
pranata H, Zijlstra F. Reperfusion therapy in elderly patients with
acute myocardial infarction: a randomized comparison of primary
angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:
1723–8.
16. Montalescot G, Barragan P, Wittenberg O, et al., ADMIRAL
Investigators. Abciximab before Direct Angioplasty and Stenting in
Myocardial Infarction Regarding Acute and Long-Term Follow-up.
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for
acute myocardial infarction N Engl J Med 2001;344:895–903.
17. The TIMI Study Group. Comparison of invasive and conservative
strategies after treatment with intravenous tissue plasminogen activator
in acute myocardial infarction: results of the Thrombolysis In Myo-
cardial Infarction (TIMI) phase II trial: the TIMI study group. N Engl
J Med 1989;320:618–27.
18. van’t Hof A, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ,
Zijlstra F. Angiographic assessment of myocardial reperfusion in
patients treated with primary angioplasty for acute myocardial infarc-
tion: myocardial blush grade. Circulation 1998;97:2302–6.
19. Zijlstra F, Ernst N, de Boer MJ, et al. Influence of prehospital
administration of aspirin and heparin on initial patency of the
infarct-related artery in patients with acute ST elevation myocardial
infarction. J Am Coll Cardiol 2002;39:1733–7.
20. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical
score for risk assessment at presentation. Circulation 2000;102:
2031–7.
21. Morishima I, Sone T, Okamura K, et al. Angiographic no-reflow
phenomenon as a predictor of adverse long-term outcome in patients
treated with percutaneous transluminal coronary angioplasty for first
acute myocardial infarction. J Am Coll Cardiol 2000;36:1202–9.
22. Golderberg RJ, McCormick D, Gurwitz JH, et al. Age-related trends
in short- and long-term survival after myocardial infarction: a 20-year
population-based perspective (1975–1995). Am J Cardiol 1998;82:
1311–7.
23. DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical
characteristics associated with increased in-hospital mortality in elderly
patients with acute myocardial infarction undergoing percutaneous
intervention (a pooled analysis of the Primary Angioplasty in Myo-
cardial Infarction Trials). Am J Cardiol 2000;86:30–4.
24. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before
mechanical reperfusion therapy is an independent determinant of
survival in acute myocardial infarction: analysis from the primary
angioplasty in myocardial infarction trials. Circulation 2001;104:
624–6.
25. Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to
treatment and mortality in patients with acute myocardial infarction
undergoing primary coronary angioplasty. Am J Cardiol 2002;89:
1248–52.
26. Flameng W, Lesaffre E, Vanhaecke J. Determinants of infarct size in
non-human primates. Basic Res Cardiol 1990;85:392–403.
27. Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute
myocardial infarction: effects of timing and modulating factors in
experimental models. Am J Cardiol 1993;72:13G–21G.
28. Garcia-Dorado D, Theroux P, Elizaga J, Fernandez Aviles F, Alonso
J, Solares J. Myocardial infarction in the pig heart model: infarct size
and duration of coronary occlusion. Cardiovasc Res 1987;21:537–44.
29. Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical
significance of distal embolization during primary angioplasty for acute
myocardial infarction. Eur Heart J 2002;23:1112–7.
30. Zijlstra F, de Boer MJ. Primary angioplasty for acute myocardial
infarction: the Zwolle approach. Semin Interv Cardiol 1999;4:55–8.
31. Brodie BR, Stuckey TD, Hansen CJ, et al. Effect of treatment delay on
outcomes in patients with acute myocardial infarction transferred from
community hospitals for primary percutaneous coronary intervention.
Am J Cardiol 2002;89:1243–7.
32. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Comparison of
Angioplasty and Prehospital Thromboysis in Acute Myocardial In-
farction study group. Primary angioplasty versus prehospital fibrino-
lysis in acute myocardial infarction: a randomised study. Lancet
2002;360:825–9.
33. Moon JC, Kalra PR, Coats AJ. DANAMI-2: is primary angioplasty
superior to thrombolysis in acute MI when the patient has to be
transferred to an invasive centre? Int J Cardiol 2002;85:199–201.
997JACC Vol. 42, No. 6, 2003 De Luca et al.
September 17, 2003:991–7 Ischemia Time and Mortality in Primary Angioplasty
